New Therapies for Pulmonary Hypertension in Neonates and Children

Pediatric Pulmonology

Volumn 37, Issue SUPPL. 26, 2004, Pages 132-135

  Aschner, Judy L ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC AMP; CYCLIC GMP; ENDOTHELIN 1; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; PROSTACYCLIN; UNIPROST; ANTIHYPERTENSIVE AGENT;

ANOREXIA; CHILDHOOD DISEASE; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CYSTIC FIBROSIS; HEADACHE; HIGH FREQUENCY OSCILLATION; HUMAN; HYPOTENSION; HYPOXEMIA; INTERSTITIAL PNEUMONIA; JAW; JAW PAIN; LUNG DYSPLASIA; LUNG MALFORMATION; NAUSEA; NEWBORN DISEASE; PAIN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY FAILURE; REVIEW; THORAX SURGERY; ARTICLE; CHILD; EXERCISE TOLERANCE; NEWBORN;

ANTIHYPERTENSIVE AGENTS; ARGININE; CHILD; ENDOTHELIN-1; EPOPROSTENOL; EXERCISE TOLERANCE; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN;

EID: 1242314329     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.70082     Document Type: Review

References (27)

1. The World Health Organization. Primary Pulmonary Hypertension Executive Summary. Stuart Rich M, editor. 1998;1-27 Evian, France.
2. Pearson DL, Dawling S, Walsh WF, Haines JL, Christman BW, Bazyk A, et al. Neonatal pulmonary hypertension-urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function. N Engl J Med 2001;344:1832-1838.
3. Kinsella JP. Meconium aspiration syndrome: is surfactant lavage the answer? Am J Respir Crit Care Med 2003;168:413-414.
4. Widlitz A, Barst RJ. Pulmonary arterial hypertension in children. Eur Respir J 2003;21:155-176.
5. Galie N, Manes A, Branzi A. Medical therapy of pulmonary hypertension. The prostacyclins. Clin Chest Med 2001;22:529-537.
6. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-1123.
7. Badesch DB, Bodin F, Channick RN, Frost A, Rainisio M, Robbins IM, et al. Complete Results of the First Randomized Placebo-Controlled Study of Bosentan, a Dual Endothelin Receptor Antagonist, in Pulmonary Arterial Hypertension. Cur Therapeutic Res 2002;63:227-246.
8. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
9. Miller OI, Tang SF, Keech A, Pigott NB, Beller E, Celermajer DS. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. Lancet 2000;356:1464-1469.
10. Dobyns EL, Cornfield DN, Anas NG, Fortenberry JD, Tasker RC, Lynch A, et al. Multicenter randomized controlled trial of the effects of inhaled nitric oxide therapy on gas exchange in children with acute hypoxemic respiratory failure. J Pediatr 1999;134:406-412.
11. Dobyns EL, Anas NG, Fortenberry JD, Deshpande J, Cornfield DN, Tasker RC, et al. Interactive effects of high-frequency oscillatory ventilation and inhaled nitric oxide in acute hypoxemic respiratory failure in pediatrics. Crit Care Med 2002;30:2425-2429.
12. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997;100:2153-2157.
13. Mehta S, Stewart DJ, Langleben D, Levy RD. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation 1995;92:1539-1545.
14. Morris CR, Morris SM, Jr., Hagar W, Van Warmerdam J, Claster S, Kepka-Lenhart D, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003;168:63-69.
15. Schulze-Neick I, Penny DJ, Rigby ML, Morgan C, Kelleher A, Collins P, et al. L-arginine and substance P reverse the pulmonary endothelial dysfunction caused by congenital heart surgery. Circulation 1999;100:749-755.
16. Gorenflo M, Zheng C, Werle E, Fiehn W, Ulmer HE. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol 2001;37:489-492.
17. Kuhn KP, Harris PA, Cunningham GR, Robbins IM, Lawson WE, Summar ML, et al. Oral Citrulline Effectively Elevates Plasma Arginine Levels for 24 Hours in Normal Volunteers. Circulation 2002;106:II-339.
18. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002;105:2398-2403.
19. Mychaskiw G, Sachdev V, Heath BJ. Sildenafil (viagra) facilitates weaning of inhaled nitric oxide following placement of a biventricular-assist device. J Clin Anesth 2001;13:218-220.
20. Kelly LK, Porta NF, Goodman DM, Carroll CL, Steinhorn RH. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J Pediatr 2002;141:830-832.
21. Kinsella JP, Truog WE, Walsh WF, Goldberg RN, Bancalari E, Mayock DE, et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr 1997;131(1 Pt 1):55-62.
22. Kinsella JP, Abman SH. Inhaled nitric oxide and high frequency oscillatory ventilation in persistent pulmonary hypertension of the newborn. Eur J Pediatr 1998;157:S28-S30.
23. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999;91:307-310.
24. Kavvadia V, Greenough A, Lilley J, Laubscher B, Dimitriou G, Boa F, et al. Plasma arginine levels and the response to inhaled nitric oxide in neonates. Biol Neonate 1999;76:340-347.
25. McCaffrey MJ, Bose CL, Reiter PD, Stiles AD. Effect of L-arginine infusion on infants with persistent pulmonary hypertension of the newbom. Biol Neonate 1995;67:240-243.
26. Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, Maniscalco WM. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;164:1971-1980.
27. Abman SH. Bronchopulmonary dysplasia: "a vascular hypothesis". Am J Respir Crit Care Med 2001;164:1755-17